4DMedical (ASX:4DX) just multiplied its addressable market sixfold with a US$2M bet

A Mass General Brigham trial pushes CT VQ into the US$2.5B acute pulmonary embolism workflow

4DMedical (ASX:4DX) has done something interesting today. It has taken roughly US$2 million, partnered with Mass General Brigham, and used it to argue that its obtainable US market is now six times larger than what most investors had been modelling.

The new program is called CLEAR. It is a head-to-head clinical study pitting CT VQ against CTPA, the contrast-based CT scan that has become the default tool for diagnosing pulmonary embolism in emergency departments. If the data lands, 4DMedical moves from chasing the roughly 1 million nuclear VQ scans done in the US each year to also chasing the roughly 5 million CTPA scans done for suspected PE.

That is the scale step-change. Management is now framing the obtainable US market for CT VQ at US$3 billion, with the PE segment alone representing around US$2.5 billion of that. For a company that has spent the last 12 months building credibility in lung volume reduction surgery and European CE Mark expansion, this is a clear pivot into acute care.

Why CTPA is such a tempting target to disrupt

CTPA usage has roughly quadrupled since 2004 despite clinical decision tools designed to slow it down. The diagnostic yield sits at just 3% to 10%, which means somewhere between 90 and 97 of every 100 patients scanned end up exposed to iodinated contrast for a clot that was not there.

That is an expensive, slightly risky workflow that emergency departments are stuck with because the cost of missing a PE is catastrophic. CT VQ promises the same answer without contrast, without nuclear isotopes, and without new hardware.

If the CLEAR data shows CT VQ matching or beating CTPA on sensitivity and specificity, the commercial case writes itself. Hospitals avoid contrast complications, radiology departments use existing scanners, and patients avoid the IV line.

Mass General Brigham is the right anchor, but it is still one site

Anchoring at Massachusetts General Hospital, the original teaching hospital of Harvard Medical School, is about as strong a launch pad as exists in US academic medicine. MGB publishes prolifically, shapes guidelines, and opens doors at other large health systems.

Our concern is that the announcement currently describes MGH as the principal enrolling site, with the option to extend to other MGB hospitals. That is a single-system study at this stage, and a US$2 million budget is small relative to the size of the prize.

The path from study launch to reimbursement decisions on a new acute-care indication typically runs years, not quarters. Today’s news opens the door, it does not walk through it.

How this fits the broader market expansion story

Founder and CEO Andreas Fouras framed this neatly in the announcement. Europe added 50% to the opportunity through the CE Mark earlier this year, and PE now multiplies it sixfold. The strategy is clearly to keep stacking adjacent markets onto the same underlying XV Technology platform.

We think that framing matters because it changes how the stock should be valued. After last year’s A$83 million placement, 4DMedical has the war chest to fund several of these wedge studies in parallel, and CLEAR may be the most ambitious because acute PE is the highest-volume indication in cardiothoracic imaging.

The Investors Takeaway for 4DMedical

Today’s announcement reframes 4DMedical from a nuclear VQ replacement story into a broader acute imaging platform play. That is a substantially bigger pitch, backed by the right academic partner, but it still rests on a study that has only just begun enrolling.

Investors should watch three things from here. Interim data signals from CLEAR, the addition of further enrolling sites beyond MGH, and continued share gain in the existing nuclear VQ replacement market that validates the core commercial engine. Readers who want our prior coverage of the Mayo deployment, CE Mark and LVRS data can find it on stocksdownunder.

Until CLEAR produces real-world comparative data, the US$2.5 billion PE opportunity sits in the company’s slide deck rather than its revenue line.